Navigation Links
Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis
Date:4/24/2008

PHOENIX, April 24 /PRNewswire/ -- Latona Life Sciences Inc. (Latona) announced today that it has entered into two agreements for the acquisition of patent rights and orphan drug status to a novel late-stage drug, trademarked "Oralgam," for the treatment of Juvenile and Adult Rheumatoid Arthritis.

Latona has entered into a licensing agreement to acquire the patent rights to Oralgam with Research Corporation Technologies, Inc., of Tucson, Arizona. Under the terms of this agreement, Latona will acquire the exclusive worldwide rights to Oralgam for the treatment of Adult Rheumatoid Arthritis and the treatment of auto-immune induced hearing loss.

Latona has also entered into a purchase and sale agreement to acquire the Orphan Drug Status, clinical data set and trademark to Oralgam with Protein Therapeutics Inc. of Tucson, Arizona. Under the terms of this agreement Latona will acquire the Orphan Drug Status to Oralgam for the treatment of Juvenile Rheumatoid Arthritis, GI Dysfunction in Autism and Dermatomyostis.

"Latona is extremely pleased to acquire the worldwide rights to Oralgam," stated Joseph Koziak, CEO of Latona. "We believe that Oralgam has the potential to provide significant relief to those who suffer from Arthritis and potential other auto-immune disorders."

About Oralgam - Oralgam is a late Phase II drug used for the treatment of immune mediated diseases. A novel product, Oralgam has shown efficacy in the treatment of juvenile arthritis in patients who have had limited success with other known pharmaceutical treatments. A platform technology, Oralgam is expected to be clinically tested in other immune mediated diseases.

About Latona Life Sciences - Latona is a privately held specialty pharmaceutical company dedicated to development and commercialization of immune mediated diseases.

About Research Corporation Technologies (RCT) - RCT (http://www.rctech.com) is a
'/>"/>

SOURCE Latona Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... , ... Real Time Pain Relief (RTPR), makers of the popular rub-on pain relief ... to sponsor The Fifth Annual Big Sky Professional Bull Riders Event being held this ... their popular pain relief lotion and products at the family friendly event that features two ...
(Date:7/2/2015)... VA (PRWEB) , ... July 02, 2015 , ... ... technology solutions and management consulting services to the federal government, has announced they ... Indefinite-Delivery, Indefinite-Quantity (IDIQ), Business Management Office Support Services (BMOSS) contract not to exceed ...
(Date:7/2/2015)... ... July 02, 2015 , ... Five individuals from Loma Linda ... for specialized disaster training. The team – composed of four clinicians and one ... Association who attended the training, which is dedicated to preparing first responders for ...
(Date:7/2/2015)... ... 02, 2015 , ... Hand sanitizers have become extremely popular with an annual ... fresh water advocate and radio host Sharon Kleyne, hand sanitizers can effectively decrease the ... effectiveness, hand sanitizers must be applied correctly and users must be aware of its ...
(Date:7/2/2015)... ... July 02, 2015 , ... B. E. Smith, ... retained to lead a national chief operating officer recruitment for Nicklaus ... the healthcare industry, B. E. Smith has recently placed more than 1,000 healthcare ...
Breaking Medicine News(10 mins):Health News:Real Time Pain Relief Sponsors The Fifth Annual Big Sky Professional Bull Riders Event at Big Sky Town Center in July 2Health News:Real Time Pain Relief Sponsors The Fifth Annual Big Sky Professional Bull Riders Event at Big Sky Town Center in July 3Health News:Octo Consulting Group Awarded IDIQ Contract for SEC Business Management Support 2Health News:Team from Loma Linda University Health Receives Specialized Disaster Training at FEMA’s Center for Domestic Preparedness 2Health News:Team from Loma Linda University Health Receives Specialized Disaster Training at FEMA’s Center for Domestic Preparedness 3Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 3Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 2Health News:Nicklaus Children’s Hospital Retains B. E. Smith to Recruit New Chief Operating Officer 3
... get fit can mean more podiatric pain, experts warn , , ... month for your tootsies, foot experts say. , ... with foot pain caused by exercise during the first month ... resolutions, according to the American College of Foot and Ankle ...
... China, Dec. 26 China Biopharma, Inc. (OTC Bulletin ... significant operational improvement after the start of corporate operational ... 30, 2008, it has made approximately $5.4 million in ... in the same period of 2007, which was approximately ...
... say findings may lead to more effective ways to control ... is better than non-aerobic activities at suppressing appetite, according to ... university students who participated in three types of sessions. In ... then rested for seven hours. In another, they did 90 ...
... can lead to pain and stiffness , , THURSDAY, Dec. 25 (HealthDay ... , To ease the backaches that may have come from ... stretching and straining to put up holiday decorations -- and that can ... Association offers a 10-step guide: , Zero in ...
... the fastest growing plastic surgery procedures among women. Changes to the ... abdomen, can be addressed in combination with a variety of plastic ... better overall contours. , ... (Vocus) December 25, 2008 ...
... 2008 Anxiety disorders in children and adolescents should ... adult substance abuse, anxiety disorders and depression, says a ... , In an editorial appearing in the Dec. 25 ... Dr. Graham Emslie, professor of psychiatry and pediatrics at ...
Cached Medicine News:Health News:Put Your Best Foot Forward Next Year 2Health News:China Biopharma, Inc. Issues Corporate Information Update 2Health News:Vigorous Treadmill Workout Curbs Appetite Hormones 2Health News:Tips to Ease an Aching Back 2Health News:South Carolina Plastic Surgeon Helps New Moms Restore their Bodies with a Mommy Makeover 2Health News:South Carolina Plastic Surgeon Helps New Moms Restore their Bodies with a Mommy Makeover 3Health News:Childhood anxiety disorders can and should be treated, according to UT Southwestern national expert 2
(Date:7/2/2015)... , 2. Juli 2015 BGI gab ... in Hongkong vom American College of Pathologists ... ist das erste klinische Next-Generation-Sequencing Labor, das ... CAP-Zertifkat erhält und somit die höchsten Standards ... bestehenden US FDA - 21 CFR Part ...
(Date:7/2/2015)... SEOUL , South Korea, July 2, 2015 ... of a new E-CUBE Series ultrasound system. Developed to ... of clinical areas, the E-CUBE 15 EX produces superb ... outstanding clinical performance in women,s health, general imaging, and ... The latest in the renowned E-CUBE Series, ...
(Date:7/2/2015)... , July 2, 2015 Legal-Bay LLC, ... District Judge Joseph Goodwin in the Southern ... consolidated 26 transvaginal mesh cases against Ethicon for a ... . The cases for the 26 women include claims ... a device made my Johnson & Johnson,s Ethicon subsidiary. ...
Breaking Medicine Technology:BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2E-CUBE 15 EX from ALPINION Enhances User Experience and Patient Care 2E-CUBE 15 EX from ALPINION Enhances User Experience and Patient Care 3Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 2Judge Sets Single Trial for 26 Ethicon Mesh Cases, says Legal-Bay Lawsuit Settlement Funding 3
... Hospitals to Invest More Resources and Take,Aggressive Steps ... U.S. healthcare,facilities aren,t doing enough to protect ... new poll of infection control professionals released today., ... for Professionals in,Infection Control (APIC) found that 59 ...
... Calif., Dec. 11 /PRNewswire-FirstCall/,-- Bristol-Myers Squibb Company ... Inc.,(Nasdaq: GILD ) today announced an ... mg/tenofovir disoproxil fumarate 300,mg) in Europe for ... infection, subject to the product,s approval by ...
Cached Medicine Technology:Survey Finds U.S. Healthcare Facilities Not Doing Enough to Curb MRSA 2Survey Finds U.S. Healthcare Facilities Not Doing Enough to Curb MRSA 3Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 2Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 3Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 4Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 5Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 6Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 7Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe 8
... containment system unit can be ... location on the top or ... added flexibility. (For replacement blower ... below.) Filters are easily ...
... Shandon Hyperclean 20 fume containment ... configuration with a swing-down front panel ... of the front opening. The ... clear acrylic which is impervious to ...
... Surgical-grade stainless steel, detachable disposable concentric ... and a 2-mm (.08-in) brass plug connector. ... The 91-cm (36-in) shielded cable with 5-pin ... cable is shipped nonsterile and may be ...
... OIA test features a dual-detection technology to ... for children under age 5 with a ... in just over 15 minutes. This combination ... to decrease costs for unnecessary ancillary testing, ...
Medicine Products: